CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children.
|
|
- Hannah Newton
- 5 years ago
- Views:
Transcription
1 Cystic Fibrosis
2 1938 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children.
3 Cystic Fibrosis : The beginning May 1938: 49 cases Nos of cases Age at death
4 Cystic Fibrosis Commonest lethal inherited condition in WW Life limiting and incurable. 600 patients in Victoria with CF. One in every 2,500 live births About new born pts per year in Vict
5 Cystic Fibrosis Median age survival late 30 s 95% survive till 20 years 80% till 30 years
6 Cystic Fibrosis New Born screening: Hits All states of Australia Day 3 2 part test: IRT and CF gene Positive results by 4-6 weeks
7 Cystic Fibrosis New Born screening 2 part test: IRT top 1% CF genotype
8 Cystic Fibrosis State New South Wales + ACT Victoria + Tasmania Mutations screened 508 p.f508, del,c.489+1g>t, c g>a, c c>t, p.1507del, p.w1282x, p.r553x, p.r560t, p.n1303k, p.g542x, p.g551d, p.v520f Queensland South Australia + Northern Territory Western Australia 508, I507, G551D, G542X, 621+1G T R553X N1303K, R117H, p.v520f 508, I507, G551D, G542X, R553X 508, G551D, G542X, 621+1G T
9 Cystic Fibrosis CF gene: Over 1900 different mutations 508 commonest - present in 90% pts in Australia Current Vic program screens for 12 commonest Mutations screened for differ between states
10 Cystic Fibrosis Transmembrane Regulator
11
12 CYSTIC FIBROSIS GENOTYPES Class 1: Premature termination of mrna translation due to base substitution causing stop codons or mutations that shift the reading frame Producing defective proteins
13
14
15
16 CYSTIC FIBROSIS GENOTYPES Class 2: Defects in protein processing CFTR is degraded in ER and does not reach apical membrane 508 and N1303K
17
18 CYSTIC FIBROSIS GENOTYPES Class 3: Regulatory mutations CFTR reaches apical membrane but fails respond to activation signals G551D
19
20 CYSTIC FIBROSIS GENOTYPES Class 4: Defective protein conduction Reaches apical membrane but has altered channel properties R117H and R347P
21
22 CYSTIC FIBROSIS GENOTYPES Class 5: Reduced levels of RNA for CFTR
23
24 Cystic Fibrosis New Born screening: Misses Chronic Cough
25
26
27
28
29 Cystic Fibrosis New Born screening: Misses Chronic Cough Failure to thrive
30 Cystic Fibrosis New Born screening: Misses Chronic Cough Failure to thrive Chronic Diarrhoea
31
32
33 Underlying defect in CF
34 Mechanisms of lung damage in CF CFTR dysfunction Viscous secretions Infection Inflammation Lung damage Abnormal lung function Death
35 CF : Early lung disease Aim to minimise/ delay onset disease thru new born screening
36 Early intervention in CF patients prevents severe malnutrition Wisconsin CF Neonatal Screening Study Randomised controlled trial with 650,000 newborns. Split into two groups: an early-diagnosis screened cohort a standard diagnosis control group Newborns screened for CF by immunoreactive trypsinogen (IRT) test ( ) IRT test + DNA-based detection of F508 ( )
37 Weight SDS Effect of screening on weight Screened Unscreened p<0.05
38 CF update: Early lung disease Aim to minimise thru NBS Regular assessments: BAL CT Scans PFT s
39 CF update: Early lung disease Regular assessments: BAL 30% infants will have Pseudomonas by age 3 Linnane B
40 CF update: Early lung disease Regular assessments: BAL 30% infants will have Pseudomonas by age 3 despite aggressive cross infection policies
41 CF update: Early lung disease Regular assessments: BAL 30% infants will have Pseudomonas by age 3 despite aggressive cross infection policies Aggressive eradication programs 85% successful
42 CF update: Early lung disease Regular assessments: BAL 30% infants will have Pseudomonas by age 3 despite aggressive cross infection policies Aggressive eradication programs 85% successful Pseudomonas EVER is a bad prognostic factor
43 CF update: Early lung disease Regular assessments: CT scans 90% infants will show signs of bronchiectasis on CT at age 5 years Wainwright C
44 CF update: Early lung disease Regular assessments: PFT s Changes occur very early and are progressive
45 Linnane B
46
47 Targeted CF update Antibiotic therapy in CF Non Pseudomonal: Staph/ H Inf
48 Total cultures (%) Incidence airway pathogens by age S. aureus H. influenzae >35 Age group (years)
49
50 CYSTIC FIBROSIS B. CEPACIA Genomovars (1-9) Aggressive lung disease (cenocepacia type 3) Non 3 mild disease Bactrim/Colistin/minocycline Some clearance
51
52 CYSTIC FIBROSIS ASPERGILLUS ABPA Airway colonisation Aspergilloma Infection in pre existing cyst
53 ABPA (ABPA) Allergic bronchopulmonary aspergillosis is a condition characterised by an exaggerated TH2 CD4+ immune response to the fungus Aspergillus (most commonly Aspergillus fumigatus). Diagnosis of ABPA in CF is difficult, and may often be delayed, because many of the diagnostic criteria overlap with common manifestations of CF
54 ABPA Classic case(all five required) 1. Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, decline in pulmonary function, increased sputum) not attributable to another etiology. 2. Serum total IgE concentration of >1000 IU/mL (2400 ng/ml), unless patient is receiving systemic corticosteroids 3. Immediate cutaneous reactivity to Aspergillus (prick skin test wheal of >3 mm with surrounding erythema, or elevated IgE antibody to A. fumigatus 4. Precipitating antibodies to A. fumigatus or serum IgG antibody to A. fumigatus 5. New or recent abnormalities on chest radiography (infiltrates or mucus plugging) or chest CT (bronchiectasis) that do not clear with Ab s and physio.
55 ABPA Minimal diagnostic criteria (all four required) 1. Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, change in pulmonary function, or increased sputum production) not attributable to another etiology. 2. Total serum IgE concentration of >500 IU/mL (1200 ng/ml) off steroids. 3. Immediate cutaneous reactivity to Aspergillus (prick skin test wheal of >3 mm or elevated specific IgE antibody to A. fumigatus. 4. One of the following: (a) precipitins to A. fumigatus or in vitro demonstration of IgG antibody to A. fumigatus; or (b) new or recent abnormalities on chest radiography
56
57 Total cultures (%) Incidence airway pathogens by age P. aeruginosa S. aureus H. influenzae >35 Age group (years)
58 Targeted CF update Antibiotic therapy in CF Main challenge is Pseudom Still limited to Tobra/ Cipro (Colistin) Cayston BD ineffective Initial eradication phase Regular cycling suppressive courses
59 Pseudomonas therapy +ve sample culture for P. aeruginosa? IV s 3 months Nebulised tobramycin Cipro Cipro Reculture: Sputum or BAL POSITIVE NEGATIVE 2 weeks of IV antipseudomonal antibiotics and then repeat No further treatment or back to prophylactic antibiotics If following second attempt of eradication sputum or BAL is still positive is likely chronic Pa infection
60 P. aeruginosa: Early colonisation to chronic infection Progression from intermittent colonisation to chronic infection coincides with activation of gene coding for alginate production
61 Pseudomonas treatment Compared the clinical and microbiological effectiveness as well as the safety of 4 antibiotic treatment strategies for newly identified P aeruginosa infection isolated from respiratory cultures in children with CF. Treggiari Arch Pediatr Adolesc Med. 2011;165(9):
62 Pseudomonas treatment 1 0 end point: Time to pulmonary exacerbation requiring IV s and % of P aeruginosa +ve cultures. Treggiari Arch Pediatr Adolesc Med. 2011;165(9):
63 Pseudomonas treatment 304 pts there were no statistically significant differences in exacerbation rates or in prevalence of Pseud between cycled and culture-based groups. Treggiari Arch Pediatr Adolesc Med. 2011;165(9):
64 Pseudomonas treatment Adding ciprofloxacin produced no benefits. Treggiari Arch Pediatr Adolesc Med. 2011;165(9):
65 P. aeruginosa: From early colonisation to chronic infection Progression from intermittent colonisation to chronic infection coincides with activation of gene coding for alginate production Transition coincides with increase in specific serum anti-p. aeruginosa antibodies (exotoxin A)
66 P. aeruginosa: From early colonisation to chronic infection Progression from intermittent colonisation to chronic infection coincides with activation of gene coding for alginate production Transition coincides with increase in specific serum anti-p. aeruginosa antibodies (exotoxin A) Activation of alginate gene may be caused by hydrogen peroxide released from activated PMNs
67 % Cumulative age of patients with chronic P. aeruginosa infection (n=55) 1980 (n=107) 1985 (n=123) 1990 (n=130) 1995 (n=131) Age (years)
68 Small airways and lung function P. aeruginosa negative - Mean % predicted of spirometry parameters P. aeruginosa positive - Mean % predicted of spirometry parameters Percent predictd Percent predictd Age in years Age in years FVC FEV FVC FEV
69 Stenotrophomonas maltophilia in CF Pts with chronic S. maltophilia infection had significantly increased risk of pulmonary exacerbation requiring hospitalization and antibiotics compared pts who had never had S. maltophilia.
70 P. aeruginosa: From early colonisation to chronic infection Macrolide antibiotics suppress alginate production in vitro Azithromycin treatment leads to increase in FVC and FEV 1 in patients with chronic P. aeruginosa infection Not effective in non Pseudomonas cases (Saiman) AZT therapy now widey used to stabilise established lung disease M,W,F or daily 250 or 500 mg Other macrolides not effective
71 Macrolide therapy in CF Clarithromycin Therapy for Patients With Cystic Fibrosis: A Randomized Controlled Trial P. Robinson, et al Pediatric Pulmonology 47: (2012).
72 Percent prevalence Prevalence of AES Range: 0.0% 44.7% AES-1 detected in 17/18 centres AES A1 (n=20) A2 (n=117) A3 (n=52) A4 (n=20) A5 (n=14) B1 (n=68) B2 (n=85) B3 (n=47) C1 (n=57) C2 (n=174) C3 (n=20) C4 (n=38) C5 (n=16) C6 (n=6) D1 (n=72) D2 (n=24) E1 (n=93) F1 (n=28) Overall (n=951) State/Centre
73 Percent prevalence Prevalence of AES Range: 0.0% 66.7% AES-2 detected in 16/18 centres AES A1 (n=20) A2 (n=117) A3 (n=52) A4 (n=20) A5 (n=14) B1 (n=68) B2 (n=85) B3 (n=47) C1 (n=57) C2 (n=174) C3 (n=20) C4 (n=38) C5 (n=16) C6 (n=6) D1 (n=72) D2 (n=24) E1 (n=93) F1 (n=28) Overall (n=951) State/Centre
74 CF update Antibiotic therapy in CF: Prophylactic Anti Staph treatment till 2 years age 50% treatment dose of Augmentin or Fluclox
75 CF update Antibiotic therapy in CF: Prophylactic Anti Staph treatment till 2 years age 50% treatment dose of Augmentin or Fluclox Anti Pseudomonal therapy (neb tobra) in select cases
76 CF update New therapies Mucolytic therapies new ones
77 CF update Mucolytic therapies New ones Inhaled mannitol Denufosol
78 CF update Mucolytic therapies New ones Inhaled mannitol Pulmozyme over 5 years age Hypertonic saline 3-6%
79 Elkins M et al. N Engl J Med 2006;354: Elkins M
80 Inhaled mannitol
81 Mannitol - A naturally occurring sugar alcohol. A potent osmotic agent Mannitol dry powder Respirable particles - 3µm No carrier Small portable inhaler No cleaning or preparation time 400mg = 10 x 40mg caps (bd) 3 5 minutes dosing time
82 Healthy Mucociliary System Mucociliary system (normal) Thin film of mucus Cilia Airway Surface Liquid Ciliated Cell Goblet Cell Submucosal glands
83 Mode of Action of Mannitol Cilia function improved 3 1 Mucus surface properties changed Goblet Cell 60 mm/s Ciliated Cell 4 Cough 2 Airway Surface Liquid reconstituted H 2 O H 2 O H 2 O H 2 O H 2 O 1. Mannitol alters the rheological properties of mucus 2. Mannitol increases the volume of airway surface liquid (ASL) 3. Mannitol has shown to have an indirect effect on cilia beat frequency in in-vitro studies 4. Mannitol promotes productive cough and assists in clearing mucus - Difference between productive cough and impact cough
84 CF-301 Mean % change in FEV 1 Bilton D, Robinson P et al. European Respiratory Journal 2011:38:
85 CF update Mucolytic therapies new uses for old ones Pulmozyme (dornase alpha)
86 Over 5 years age: CF update: Pulmozyme (dornase alpha) 1 month trial showing 10% increase in FEV1 for continued therapy
87 Over 5 years age: CF update: Pulmozyme (dornase alpha) 1 month trial showing 10% increase in FEV1 for continued therapy Removed 2013 now clinical grounds only Under 5 years age: Severe clinical course with > 3 admits Signif bronchiectasis on CT scan Severe CF bronchiolitis with persistent, resistant wheeze Severe impairment on spirometry (FOT or MBW)
88 CF update New therapies: Mutation specific therapies Vertex trials: G551D
89
90 Vx 102 and 103 trials Evaluate the efficacy of VX-770 after 24 weeks of treatment in subjects with CF who have the G551D-cystic fibrosis trans membrane conductance regulator (CFTR) mutation on at least 1 allele 102 CF pts above 12 years 103 CF 6-12 years 105 open label extension
91 VX-770 Phase III Study Design 102 Screening Randomization (1:1) VX mg q12h Run-in Primary analysis VX mg q12h Open-label rollover study VX mg q12h Placebo Placebo Or 2-yr Follow-up Day Week Treatment period Extension period Randomized, double-blind, placebo-controlled Recruitment: 161 subjects Key inclusion criteria G551D mutation on at least one CFTR allele Aged 12 years FEV 1 40% to 90% predicted
92 Absolute Change in FEV 1 % Predicted 15 Placebo VX-770 Absolute change in % predicted FEV1 (mean, 95% CI) Treatment effect through Week % P < Treatment effect through Week % P < Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
93 Change from Baseline in Sweat Chloride 5 0 Change in sweat chloride concentration mmol/l (mean, 95% CI) Placebo VX-770 Treatment effect through Week mmol/l P < Treatment effect through Week mmol/l P < Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
94 Change from Baseline in CFQ-R Resp Domain Treatment effect through Week P < Treatment effect through Week P < Change in CFQ-R respiratory domain points (mean, 95% CI) Placebo VX-770 MCID = 4* Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48 * MCID, minimal clinically important difference (Quittner et al 2009)
95 Proportion of event-free subjects Time to First Pulmonary Exacerbation Week 24 Hazard Ratio 0.40 P = Week 48 Hazard Ratio 0.46 P = Placebo VX PLACEBO VX-770 Event-Free Rate At Week Hazard Ratio: 0.45 ( 0.28, 0.73) P= Study day
96 Change from Baseline in Weight 5 Placebo VX-770 Treatment effect at Week kg P < Treatment effect at Week kg P = Change in weight kg (mean, 95% CI) Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
97
98 Lumicaftor 2 part medication Ivacaftor 3-4% increase in lung function
99 CF update Complications of getting older Diabetes 20% CFRD by age of 20 years and up to 50% by mid thirties Annual endocrine review after age 12 with consideration of OGTT annually
100
101
102
103
104 CF Related Diabetes mellitus (CFRD) 60% non-diabetic pts vs 25% diabetic pts lived to 30 yrs US study, 21% CF patients with long-term diabetes had microangiopathy, retinopathy, neuropathy, nephropathy
105
106
107 Miscellaneous GI manifestations Cancer: Increased freq of small bowel, colon, biliary tract No increase in stomach or rectum Coeliac: Previously thought to be increased but now found 10 times less common. C. Difficile: High carriage rate 2 0 to broad spectrum Ab s Crohn s: IBD 7 times more common, Crohns 17 times.
108 Osteoporosis in CF
109 Osteoporosis in CF Increasingly recognised in adults and children > 12 Children: 62 pts mean Z score (spine) and 0.71 femoral neck. (Henderson). Adults: mean Z score (spine) and (femoral neck)
110 Osteoporosis in CF Multifactorial Malabsorption of Vit D and Calcium Low body weight, Decreased physical activity Hypogonadism, Osteolytic activity circulating cytokines, Amenorrhea Steroid usage diabetes Chronic infection, Delayed puberty
111 CYSTIC FIBROSIS DIAGNOSIS Gold standard sweat test Clinically think fat malabsorption Prop develop PI nearer 12 months 5-10% PS 95% destrn
112 CYSTIC FIBROSIS PANCREATIC INSUFFICENCY Steathorrea most clinical obvious Enzymes contain all 3 enzymes Enteric coated Acidic small bowel Acid reducing agents
113 Cystic Fibrosis BOSTON TORONTO n=499 (15.9yrs) n=534 (15.2yrs) 58% males 57% males Fat restriction High fat diet FEV1 = FEV1
114 Cystic Fibrosis BOSTON TORONTO n=499 (15.9yrs) n=534 (15.2yrs) 58% males 57% males Fat restriction High fat diet FEV1 = FEV1 BUT Median survival 21 years 30 years
115 ASL
116 ASL In newborn wild-type pigs, the ASL rapidly kills bacteria in vivo, when removed from the lung and in primary epithelial cultures. Lack of CFTR reduces bacterial killing. AA Pezzulo et al. Nature 487, (2012)
117 P. aeruginosa-coated grids placed on HBE S. Aureus-coated grids placed on HBE AA Pezzulo et al. Nature 487, (2012)
118 ASL Found that the ASL ph was more acidic in CF pigs, and reducing ph inhibited the antimicrobial activity of ASL.
119 ASL Without CFTR, airway epithelial HCO3 secretion is defective, the ASL ph falls and inhibits antimicrobial function, thereby impairing the killing of bacteria that enter the newborn lung.
120 Hypertonic saline
121 Nebulised Hypertonic Saline (HTS) CF lung inflammation mediated inflam chemokines, incl IL-8. IL8 protected proteolytic degradation by binding to glycosaminoglycans Reeves Am J Respir Crit Care Med 2011; 183
122 Nebulised Hypertonic Saline (HTS)? anti-inflammatory effect of HTS in CF lung by focusing on IL-8 CF IL-8 levels significantly higher than the control group Digesting glycosaminoglycans in CF BALF displaced IL-8 from glycosaminoglycan matrices, rendering the chemokine susceptible to proteolytic cleavage. Reeves Am J Respir Crit Care Med 2011; 183
123 Reeves Am J Respir Crit Care Med Vol
124 Nebulised Hypertonic Saline (HTS) Nebulized HTS tx disrupts the interaction between IL-8 and glycosaminoglycans, rendering IL-8 susceptible to proteolytic degradation with subsequent decrease in neutrophil chemotaxis, facilitating resolution of inflammation. Reeves Am J Respir Crit Care Med Vol
125 Inhaled hypertonic saline in CF children < 6 yrs. Multicenter, randomized, double-blind, placebo-controlled trial at 30 US CF centers in children 4-60 months. Active treatment (158) received 7% HTS Control group (163) received 0.9% isotonic saline, nebulized bd for 48 weeks. Mean pulmonary exacerbation rate was; 2.3 in HTS group and 2.3 in controls pts. Rosenfeld ISIS Study Group. JAMA. 307(21): , 2012
126
127 Inhaled hypertonic saline in CF children < 6 yrs No significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores. Rosenfeld ISIS Study Group. JAMA. 307(21): , 2012
128 Bugs and drugs
129 Pseudomonas and Females Estradiol and estriol induced alginate production in P. aeruginosa strain 01 and in clinical isolates obtained from patients with and those without CF. After prolonged exposure to estradiol, P. aeruginosa adopts mucoid morphology Frameshift mutation was identified in muca, a key regulator of alginate biosynthesis in P. aeruginosa In vivo levels of estradiol correlated with infective exacerbations in women with CF, with majority occurring during the follicular phase Chotirmall N Eng J Med May 2012
130 Chotirmall N Eng J Med May 2012
131 Pseudomonas and Females Predominantly nonmucoid P. aeruginosa was isolated from sputum during exacerbations in the luteal phase (low estradiol). Increased proportions of mucoid bacteria were isolated during exacerbations occurring in the follicular phase (high estradiol), Chotirmall N Eng J Med May 2012
132 Azt autophagy Autophagy: degradation of a cell's own components through the lysosomal system. Autophagy appears crucial for an effective cellular response against mycobacteria including NTM. Macrolide bafilomycin is known to disrupt autophagy in vitro. Renna The Journal of Clinical Investigation 2011;121;(9)
133 Azt autophagy Studies have identified synchronous increase in mycobacterial infection of CF pts, predominantly with the multi-drug-resistant, highly pathogenic nontuberculous mycobacteria Mycobacterium abscessus. Postulated azithromycin paradoxically impairs host immunity against mycobacteria. Renna The Journal of Clinical Investigation 2011;121;(9)
134 Azt autophagy Studies have identified synchronous increase in mycobacterial infection of CF pts, predominantly with the multi-drug-resistant, highly pathogenic nontuberculous mycobacteria Mycobacterium abscessus. Postulated azithromycin paradoxically impairs host immunity against mycobacteria. Renna The Journal of Clinical Investigation 2011;121;(9)
135 RENAL DISEASE IN CF CFRD requiring insulin therapy substantially increased the risk of chronic kidney disease. Pulmonary exacerbations did not significantly increase the risk of chronic kidney disease.
136 Pseudomonas aeruginosa Type-3 Secretion System Dampens Host Defense by Exploiting the NLRC4-coupled Inflammasome
137 Structures of needle proteins and their complexes. Blocker A J et al. PNAS 2008;105: by National Academy of Sciences
138 By capping the TSSS there would be less intracellular injection of bacterial toxins and less cell injury.
139 Cellular inflammation During an infection, one of the first forms of defense employed by the innate immune response is a group of pattern recognition receptors (PRRs) encoded in the germline to recognize molecular patterns expressed by invading pathogens. May either be on the membrane surface e.g. Toll-like receptors (TLRs) and C-type Lectin Receptors (CLRs) or inside the cytoplasm e.g. Nod-like receptors (NLRs). Nod = nucleotide-binding oligomerization domain receptors Oligomerization (chemistry) The formation of an oligomer from a monomer
140 INFLAMMASOME In 2002, it was reported that a subset of NLRs named NLRP1 were able to assemble and oligomerize into a common structure which collectively activated the caspase-1 cascade, thereby leading to the production of pro-inflammatory cytokines especially IL-1B and IL-18. This NLRP1 multi-molecular complex was dubbed the inflammasome. Since then, several other inflammasomes were discovered, two of which are also NLR subsets NLRP3 and NLRC4
141
142
143
144 Pseudomonas aeruginosa triggers, through a functional type-3 secretion system (T3SS), the activation of an intracellular cytosolic sensor of innate immunity, NLRC4.
145 Pseudomonas aeruginosa triggers through a functional type- 3 secretion system (T3SS), the activation of an intracellular cytosolic sensor of innate immunity, NLRC4. However, NLRC4-inflammasome dependent response contributes to increased clearance of intracellular pathogens, while Pseudomonas is an extracellular pathogen.
146 Congenital abnormalities Laryngomalacia Clinical diagnosis Bronchoscopy for Diff Dx Resolution 2-3 years Residual insp flow limitation
147 Congenital abnormalities Laryngomalacia Clinical diagnosis Bronchoscopy for Diff Dx Resolution 2-3 years Residual insp flow limitation Diff Dx: tracheomalacia, sub-glottic haemangioma, sug glottic cyst, paralysed vocal cord
148
149 Congenital abnormalities Tracheomalacia: Isolated, 2 0 TOF, Cartilage rings, stenosis aberrant airway anatomy External compression Bronchogram vs bronchoscopy Stenting
150
151 Congenital abnormalities Tracheomalacia: 2 0 TOF, vascular ring Surgical repair does not improve Pulm fnctn in short term Dying spells
152 Congenital abnormalities Pulmonary hypoplasia: Isolated Compression diaph hernia Reduced lung function Check vascular anatomy
153 Bronchopulmonary Sequestration A non-functioning mass of lung tissue that lacks normal communication with the tracheobronchial tree and receives its arterial blood supply from the systemic circulation usually from the thoracic or abdominal aorta. 2 types based on the nature of their pleural covering. Extralobar sequestration is a mass of pulmonary parenchyma with a distinct pleura covering separating it from the adjacent normal lung. Intralobar sequestration is located within a normal lobe and lacks its own visceral pleura. Both types are composed of normal lung tissue, including airway and alveolar elements.
154
155 Bronchopulmonary Sequestration Histologically, pulmonary sequestrations demonstrate immature lung development. Extralobar sequestrations have anomalous blood supply from an infradiaphragmatic source in about 20% of patients.
156 Bronchopulmonary Sequestration Intralobar sequestrations appear similar, on prenatal ultrasound, to a CPAM. Can be associated with pleural effusion, polyhydraminos, and nonimmune hydrops fetalis. Can be difficult to differentiate from a CPAM or CDH by prenatal ultrasound. 60% occur on the left side, most commonly left lower lobe. 90% extralobar sequestrations are located in the left hemithorax within the posterior mediastinum. Sequestration in the upper lobe occurs in only 10 15%, and bilateral sequestrations are rare.
157 Bronchopulmonary Sequestration Extralobar sequestrations generally present earlier than intralobar. Infants with extralobar sequestrations typically present with respiratory distress and less commonly with recurrent pneumonia. Intralobar sequestration usually present in late childhood or adolescence with recurrent pulmonary infections.
158 Bronchopulmonary Sequestration Extralobar sequestrations often identified on antenatal U/S or in infancy during surgery for other congenital anomalies such as CPAM or CDH. Most intralobar sequestrations present later in childhood due to recurrent pulmonary infections. The abnormally developed lung tissue is ineffective in gas exchange and therefore is not of benefit to the patient. Spontaneous involution of extralobar sequestrations has been described
159 Bronchopulmonary Sequestration Symptomatic patients, treatment is surgical excision, curative and is associated with minimal morbidity. Sx may be immediately after birth in severe RDS. Or electively in older children who present with recurrent infections.
160
161 Intralobar pulmonary sequestration. CT scan showing calcified mass in left lower lobe
162 Congenital pulmonary airway malformations (CPAM) Previously congenital cystic adenomatoid malformations (CCAM) Benign hamartomas or dysplastic tumors characterized by overgrowth of terminal bronchioles in a glandular/adenomatoid pattern. Constitute 10 30% of congenital lung malformations. Thought to result from marked overgrowth of the terminal bronchioles at the expense of alveoli development.
163 Congenital pulmonary airway malformations (CPAM) Generally unilobar with a slight predilection for the lower lobes, with right and left sides affected equally. Typically, have normal pulmonary arterial and venous blood supply and communicate with the tracheobronchial tree. Prenatal diagnosis by sonography is relatively common
164 Congenital pulmonary airway malformations (CPAM) Natural history determined more by overall size and degree of compression of adjacent structures than by their gross appearance. Prenatal DDx includes congenital diaphragmatic hernia, pulmonary sequestration, and bronchogenic cyst. U/S findings associated with CPAM include polyhydramnios, mediastinal shift, pleural effusions, and fetal hydrops
165
166
167 Congenital pulmonary airway malformations (CPAM) In antenatal and immediate postnatal period, main physiologic consequence of CPAM results from compression of the mediastinum and adjacent normal lung by the mass lesion. Fetal hydrops identified in 40% of fetuses with CPAM and historically was an ominous finding, associated with a high risk of fetal or neonatal demise. Mortality approaches zero for a fetus with a CPAM but without hydrops Spontaneous resolution in-utero of an antenatally diagnosed CPAM is reported in up to 15% of patients
168 Congenital pulmonary airway malformations (CPAM) Most asymptomatic or undiagnosed CPAM will present with infectious complications during childhood or adolescence if not resected. 10% infectious complications by 3 yrs with unresected CPAM. Pneumothorax and bronchiectasis are reported in association with an untreated CPAM. Less commonly, a CPAM is diagnosed in a child or during adulthood in association with a pulmonary malignancy.
169 Congenital Lobar Emphysema (CLO) Characterized by expiratory air trapping within affected lobe. Air trapping leads to overdistension of the affected lobe and compression of the adjacent lung and mediastinal structures. Lung parenchyma is typically normally developed, bronchial collapse is commonly seen due to a focal deficiency or absence of the cartilaginous components of the lobar Bronchus.
170
171 Congenital Lobar Emphysema Dx CLE is rarely made by antenatal US or MRI as process of air trapping occurs postnatally. Most commonly, the Dx CLE is made by plain chest X-ray in newborn with RDS. Most often affects the left upper lobe (40 50%), followed by right middle lobe (30 40%), right upper lobe (20%).
172 Congenital Lobar Emphysema Associated with congenital heart disease in approximately 15% of patients and therefore screening echocardiography is recommended. 50% affected infants will demonstrate signs of respiratory distress in the first few days of life; the remainder develop symptoms within the first few months or years of life.
173 Bronchogenic Cysts Bronchogenic cysts are typically thick walled, unilocular cysts that originate from either the trachea or bronchus. Believed to occur as a result of abnormal budding of the tracheobronchial tree; hence can be found anywhere along the conducting airways.
174 Bronchogenic Cysts Most often located within the lung parenchyma, mediastinum, or in the neck; but ectopic bronchogenic cysts have been reported in paravertebral, paraesophageal, pericardial, subcarinal, and subcutaneous locations. Many bronchogenic cysts are asymptomatic and discovered incidentally by chest radiography.
175 Bronchogenic Cysts Most infants present with wheezing, tachypnea, dyspnea, and cyanosis or less commonly, failure to thrive as a result of compression of adjacent mediastinal structures. Older children typically present with infectious complications. Resection is typically indicated to alleviate symptoms, prevent future infection, and to provide pathologic identification.
Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.
1938 OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children. : The beginning May 1938: 49 cases 25 20 15 Nos of cases 10 5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Age
More informationCongenital Lung Malformations: Radiologic-Pathologic Correlation
Acta Radiológica Portuguesa, Vol.XVIII, nº 70, pág. 51-60, Abr.-Jun., 2006 Congenital Lung Malformations: Radiologic-Pathologic Correlation Marilyn J. Siegel Mallinckrodt Institute of Radiology, Washington
More informationCystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
More informationWhat is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
More informationImaging of the Lung in Children
Imaging of the Lung in Children Imaging methods X-Ray of the Lung (Anteroposterior, ) CT, HRCT MRI USG Congenital developmental defects of the lungs Agenesis, aplasia, hypoplasia Tension pulmonary anomalies
More informationSurgical indications: Non-malignant pulmonary diseases. Punnarerk Thongcharoen
Surgical indications: Non-malignant pulmonary diseases Punnarerk Thongcharoen Non-malignant Malignant as a pathological term: Cancer Non-malignant = not cancer Malignant as an adjective: Disposed to cause
More informationCystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS
Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =
More information"Management and Treatment of Patients with Cystic fibrosis (CF)
"Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March
More informationRespiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationLung sequestration and Scimitar syndrome
Lung sequestration and Scimitar syndrome Imaging approaches M. Mearadji International Foundation for Pediatric Imaging Aid Rotterdam, The Netherlands Pulmonary sequestration Pulmonary sequestration (PS)
More informationCystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
More informationTransformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs
Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41
More informationThere are four general types of congenital lung disorders:
Pediatric Pulmonology Conditions Evaluated and Treated As a parent, watching a child suffer from a respiratory disorder can be frightening and worrisome. Our respiratory specialists provide compassionate
More informationHOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF
HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF Peter D. Sly MBBS, MD, FRACP, DSc OUTLINE Goals of CF treatment Drivers of early disease neutrophilic inflammation oxidative stress
More informationNON-CF BRONCHIECTASIS IN ADULTS
Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology
More informationBronchiectasis in Adults - Suspected
Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors
More informationCystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically
More informationCase Report Coexistent Congenital Diaphragmatic Hernia with Extrapulmonary Sequestration
Canadian Respiratory Journal Volume 2016, Article ID 1460480, 4 pages http://dx.doi.org/10.1155/2016/1460480 Case Report Coexistent Congenital Diaphragmatic Hernia with Extrapulmonary Sequestration Nao
More informationEvaluation of Patients with Diffuse Bronchiectasis
Evaluation of Patients with Diffuse Bronchiectasis Dr. Patricia Eshaghian, MD Assistant Clinical Professor of Medicine Director, UCLA Adult Cystic Fibrosis Affiliate Program UCLA Division of Pulmonary
More informationA review of Cystic Fibrosis
A review of Cystic Fibrosis Jennifer Landry md F.R.C.P.(C) Pulmonary & Critical Care Medicine McGill University Health Center Cystic Fibrosis One of the most common lethal inherited AR disorders in the
More informationGoals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy
CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More information4.6 Small airways disease
4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationCystic Fibrosis Foundation Patient Registry 2013
5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical
More informationCystic fibrosis: hitting the target
Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas
More informationChanges in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses
Changes in the management of children with Cystic Fibrosis Caroline Murphy & Deirdre O Donovan CF Nurses What Is Cystic Fibrosis? Cystic fibrosis (CF) is an inherited chronic disease that primarily affects
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationFungal (Aspergillus and Candida) infections in Cystic fibrosis
Fungal (Aspergillus and Candida) infections in Cystic fibrosis Malena Cohen-Cymberknoh, MD CF Center Hadassah-Hebrew University Medical Center Jerusalem, Israel Israeli Annual CF Conference, Herzlyia,
More informationCYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
More informationCystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis
Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis APRIL 2018 Authors Steve Kent MD, CF Clinic Director, Victoria General Hospital (VGH), Victoria Mark Chilvers MD, CF Clinic Director, B.C.
More informationCystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
More informationEfficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Vallières, E., Tumelty, K., Tunney, M. M., Hannah, R., Hewitt, O., Elborn, J. S., & Downey, D. G. (2017). Efficacy of Pseudomonas
More informationNon-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX
Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX Pioneer of Respiratory Medicine 2016 marked 200th anniversary of his
More informationCystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL
Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Objectives: At the end of the presentation the listeners will Be able to describe neonatal
More informationEnabling CF Therapeutic Development
Enabling CF Therapeutic Development PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs No Disclosures Cystic Fibrosis In 1955 In 1955 most children with CF did not live long enough
More informationCase Based Fetal Lung Masses
Case Based Fetal Lung Masses Advances in Fetal and Neonatal Imaging Course Orlando, Florida, January 28, 2017 Leann E. Linam, MD Associate Professor Radiology University of Arkansas for Medical Sciences/
More informationPediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.
Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival
More informationDisclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016
Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy Susanna A McColley, MD Associate Chief Research Officer Stanley Manne Children s Research Institute
More informationPulmonary Sequestration
July 26, 2004 Pulmonary Sequestration Jonathan Shaw, Harvard Medical School Year IV What do these two patients have in common? Patient 1: 50 y.o. non-smoking female with several months cough and hemoptysis;
More informationClinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)
Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults) Reference: NHS England 1621 First published: Month Year Prepared
More informationFocus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis
Focus on (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Autosomal recessive, multisystem
More informationMolla Teshome MD, Habtamu Belete MD Aurora Health Care Internal Medicine Residency Program
Molla Teshome MD, Habtamu Belete MD Aurora Health Care Internal Medicine Residency Program History 32 year-old male who presented with a 4 days history of: Productive cough Right sided pleuritic chest
More informationISUOG Basic Training. Assessing the Neck & Chest Gihad Chalouhi, Lebanon
ISUOG Basic Training Assessing the Neck & Chest Gihad Chalouhi, Lebanon Learning objectives 9 & 10 At the end of the lecture you will be able to: recognise the differences between the normal & most common
More informationPULMONARY VENOLOBAR SYNDROME. Dr.C.Anandhi DNB Resident, Southern Railway Headquarters Hospital.
PULMONARY VENOLOBAR SYNDROME Dr.C.Anandhi DNB Resident, Southern Railway Headquarters Hospital. Presenting complaint: 10 yrs old girl with recurrent episodes of lower respiratory tract infection from infancy.
More informationClinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages)
Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages) NHS England Reference: 1732P NHS England INFORMATION READER BOX Directorate
More informationCHAPTER 7.1 STRUCTURES OF THE RESPIRATORY SYSTEM
CHAPTER 7.1 STRUCTURES OF THE RESPIRATORY SYSTEM Pages 244-247 DO NOW What structures, do you think, are active participating in the breathing process? 2 WHAT ARE WE DOING IN TODAY S CLASS Finishing Digestion
More information24. An infant with recurrent pneumonia underwent a frontal chest radiograph (Fig 24-A) followed by
24. An infant with recurrent pneumonia underwent a frontal chest radiograph (Fig 24-A) followed by diagnosis? ndings, what is the most likely A. Pulmonary sequestration B. Congenital pulmonary airway malformation
More informationBronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago
Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have
More informationA Genetic Approach to the Treatment of Cystic Fibrosis
A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March
More informationAsthma. - A chronic inflammatory disorder which causes recurrent episodes of wheezing, breathlessness, cough and chest tightness.
Obstructive diseases Asthma - A chronic inflammatory disorder which causes recurrent episodes of wheezing, breathlessness, cough and chest tightness. - Characterized by Intermittent and reversible (the
More informationA Place For Airway Clearance Therapy In Today s Healthcare Environment
A Place For Airway Clearance Therapy In Today s Healthcare Environment Michigan Society for Respiratory Care 2015 Fall Conference K. James Ehlen, MD October 6, 2015 Objectives Describe patients who will
More informationCCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017
Physician / Patient Conference, Georgetown University, May 2017 Bronchiectasis Treatment Antibiotics Charles Haworth CCLI Cambridge Centre for Lung Infection Disclosures Educational talks and / or consultancy
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance
More informationUK Cystic Fibrosis Registry
UK Cystic Fibrosis Registry Annual Data Report 2017 Scotland UK Cystic Fibrosis Registry 2017 Annual Data Report - Scotland Report prepared by Andrew Lee Statistician Cystic Fibrosis Trust Susan Charman
More informationLung Disease in Pediatrics: is it all in the Genes?
Lung Disease in Pediatrics: is it all in the Genes? Jay K. Kolls, M.D. Chair, Department of Genetics LSU Health Sciences Center New Orleans, LA Children s s Hospital of Pittsburgh Severe combined immunodeficiency
More information1. Introduction. Obstructive lung disease remains the leading cause of morbidity and mortality in cystic fibrosis
1. Introduction Obstructive lung disease remains the leading cause of morbidity and mortality in cystic fibrosis (CF) [1]. With time it has become increasingly clear that CF lung disease is present very
More informationLung- and airway emergencies
Lung- and airway emergencies Charlotte de Lange,MD,PhD Pediatric Radiology unit, Oslo University Hospital, Norway 5th Nordic course - Emergency Radiology Oslo 18-21.5.2015 clange@ous-hf.no How come pediatric
More informationPULMONARY EMERGENCIES
EMERGENCIES I. Pneumonia A. Bacterial Pneumonia (most common cause of a focal infiltrate) 1. Epidemiology a. Accounts for up to 10% of hospital admissions in the U.S. b. Most pneumonias are the result
More informationJournal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010
Journal Club The ELITE Trial Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010 Overview Journal article Title, journal, authors, funding Abstract Introduction
More informationChronic obstructive lung disease. Dr/Rehab F.Gwada
Chronic obstructive lung disease Dr/Rehab F.Gwada Obstructive lung diseases Problem is in the expiratory phase Lung disease Restrictive lung disease Restriction may be with, or within the chest wall Problem
More informationPediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives
Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other
More informationBronchiectasis: An Imaging Approach
Bronchiectasis: An Imaging Approach Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco Large Middle Small 1 Bronchiectasis
More informationMedical / Microbiology
Medical / Microbiology Pseudomonas aeruginosa biofilms in the lungs of Cystic Fibrosis Patients Thomas Bjarnsholt, PhD, Associate professor 1,2, Peter Østrup Jensen, PhD 2 and Niels Høiby, MD, Dr. Med,
More information11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.
The spectrum of pulmonary diseases in HIV-infected persons is broad. HIV-associated Opportunistic infections Neoplasms Miscellaneous conditions Non HIV-associated Antiretroviral therapy (ART)-associated
More informationChronic lung diseases in children Simple choice 1. Finger clubbing is not characteristic for: a) Diffuse bronchiectasis b) Cystic fibrosis c)
Chronic lung diseases in children Simple choice 1. Finger clubbing is not characteristic for: a) Diffuse bronchiectasis b) Cystic fibrosis c) Bronchiolitis obliterans d) Complicated acute pneumonia e)
More information5/5/2013. The Respiratory System. Chapter 16 Notes. The Respiratory System. Nasal Cavity. Sinuses
The Respiratory System Chapter 16 Notes The Respiratory System Objectives List the general functions of the respiratory system. Identify the organs of the respiratory system. Describe the functions of
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf
More informationBronchiectasis. What is bronchiectasis? What causes bronchiectasis?
This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis
More informationYou Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM
You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative
More informationCongenital lung anomalies: can we postpone resection?
Journal of Pediatric Surgery (2012) 47, 87 92 www.elsevier.com/locate/jpedsurg Congenital lung anomalies: can we postpone resection? Nadja Colon a, Cameron Schlegel a, John Pietsch a, Dai H. Chung a,b,
More informationMacrolide therapy in cystic fibrosis: new developments in clinical use
Macrolide therapy in cystic fibrosis: new developments in clinical use Clin. Invest. (2013) 3(12), 1179 1186 Macrolide therapy, in particular azithromycin, has been shown to improve aspects of lung health
More informationA Quick Guide to the. I507del. Mutation CFTR SCIENCE
A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationInhaled Antibiotics in Non-CF. Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom
Inhaled Antibiotics in Non-CF Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom Advantages Increased drug concentrations locally Reduced systemic adverse effects Home
More informationNON-CYSTIC FIBROSIS BRONCHIECTASIS
NON-CYSTIC FIBROSIS BRONCHIECTASIS MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the
More informationRecent advances in diagnosis and management of ABPA. Arindam SR(Pulmonary Medicine)
Recent advances in diagnosis and management of ABPA Arindam SR(Pulmonary Medicine) Conventional diagnostic criteria for ABPA Primary Episodic bronchial obstruction (asthma) Peripheral blood eosinophilia
More informationHOW TO IMAGE AND DESCRIBE CONGENITAL LUNG MALFORMATIONS
HOW TO IMAGE AND DESCRIBE CONGENITAL LUNG MALFORMATIONS Paul Thacker, MD Assistant Professor Departments of Radiology and Pediatrics Medical University of South Carolina DISCLOSURES I have no relevant
More informationBronchial syndrome. Atelectasis Draining bronchus Bronchiectasis
Bronchial syndrome Atelectasis Draining bronchus Bronchiectasis Etienne Leroy Terquem Pierre L Her SPI / ISP Soutien Pneumologique International / International Support for Pulmonology Atelectasis Consequence
More informationCYSTIC FIBROSIS Risk Factors Epidemiology Pathogenesis Defective protein synthesis (10%) Abnormal protein folding, processing & trafficking
CYSTIC FIBROSIS Risk Factors Caucasian Family history of CF Infection Exposure to allergens and tobacco Epidemiology Carrier frequency of 1 in 25 for Caucasians The most common lethal genetic disease affecting
More informationBronchiectasis. Introduction. Key points
15 Bronchiectasis Introduction i Key points Patients with bronchiectasis typically have chronic airway infection, punctuated by acute exacerbations and accompanied by progressive airflow obstruction. Bronchiectasis
More informationRespiratory Diseases and Disorders
Chapter 9 Respiratory Diseases and Disorders Anatomy and Physiology Chest, lungs, and conducting airways Two parts: Upper respiratory system consists of nose, mouth, sinuses, pharynx, and larynx Lower
More information1. The barriers of the innate immune system to infection
Section 3.qxd 16/06/05 2:11 PM Page 12 12 SECTION THREE: Fleshed out 1. The barriers of the innate immune system to infection Questions What are the three characteristics of the innate immune system? What
More informationBronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh
Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.
More informationThe Future of CF Therapy
The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex
More information10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
More informationIt s Rare So Be Aware: Pleuropulmonary Blastoma Mimicking Congenital Pulmonary Airway Malformation
e10 Case Report: Thoracic THIEME It s Rare So Be Aware: Pleuropulmonary Blastoma Mimicking Congenital Pulmonary Airway Malformation Fayza Haider 1 Khulood Al Saad 2 Fatima Al-Hashimi 3 Hakima Al-Hashimi
More informationUNDERSTANDING CYSTIC FIBROSIS
UNDERSTANDING CYSTIC FIBROSIS INTRODUCTION Cystic fibrosis is a chronic disease that affects the respiratory and gastrointestinal systems. People with cystic fibrosis have a genetic defect of the lungs
More informationSubject Index. Bacterial infection, see Suppurative lung disease, Tuberculosis
Subject Index Abscess, virtual 107 Adenoidal hypertrophy, features 123 Airway bleeding, technique 49, 50 Airway stenosis, see Stenosis, airway Anaesthesia biopsy 47 complications 27, 28 flexible 23 26
More informationHeart and Lungs. LUNG Coronal section demonstrates relationship of pulmonary parenchyma to heart and chest wall.
Heart and Lungs Normal Sonographic Anatomy THORAX Axial and coronal sections demonstrate integrity of thorax, fetal breathing movements, and overall size and shape. LUNG Coronal section demonstrates relationship
More informationPULMONARY TUBERCULOSIS RADIOLOGY
PULMONARY TUBERCULOSIS RADIOLOGY RADIOLOGICAL MODALITIES Medical radiophotography Radiography Fluoroscopy Linear (conventional) tomography Computed tomography Pulmonary angiography, bronchography Ultrasonography,
More informationPULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM
PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM Pulmonary surfactant Pulmonary surfactant is (phospholipoprotein) complex
More informationUnit II Problem 2 Pathology: Pneumonia
Unit II Problem 2 Pathology: Pneumonia - Definition: pneumonia is the infection of lung parenchyma which occurs especially when normal defenses are impaired such as: Cough reflex. Damage of cilia in respiratory
More informationPseudomonas aeruginosa eradication guideline
SCOTTISH PAEDIATRIC CYSTIC FIBROSIS MCN Pseudomonas aeruginosa eradication guideline Date Created: 27 th June 2013 Date Approved by Steering Group: 30 th May 2014 Date of Review: 31 st May 2016 Lead Author:
More informationQuestions 1-3 refer to the following diagram. Indicate the plane labeled by the corresponding question number.
Name: Grade: ANATOMY TEST Questions 1-3 refer to the following diagram. Indicate the plane labeled by the corresponding question number. 1. Plane #1 is the... 2. Plane #2 is the... 3. Plane #3 is the...
More informationMai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012
Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Recognize the importance of Pulmonary Function Testing in Cystic Fibrosis Be aware of different types
More informationDisease spectrum. IPA Invasive pulmonary aspergillosis
Aspergillus & ABPA Disease spectrum IPA Invasive pulmonary aspergillosis ABPA ABPA pathophysiology conidia of Aspergillus trapped in mucous and narrowed airways of asthmatics/cf germinate to form hyphae
More informationThe Respiratory System. Dr. Ali Ebneshahidi
The Respiratory System Dr. Ali Ebneshahidi Functions of The Respiratory System To allow gases from the environment to enter the bronchial tree through inspiration by expanding the thoracic volume. To allow
More informationPalliative and Supportive Care in Cystic Fibrosis
Palliative and Supportive Care in Cystic Fibrosis Dr William Flight Consultant in Respiratory Medicine Oxford Adult Cystic Fibrosis Centre 27 th January 2017 Overview 1. Cystic Fibrosis Clinical Aspects
More information